The Subjective Nature of “Safe and Tolerable” Conclusions
Hematologist/oncologist Aaron Gerds, MD examines the subjectivity of clinical trial conclusions
When referring to early-phase trial results, researchers often conclude that a therapy was safe and well-tolerated. But what does this statement really mean? In his latest Editor’s Corner column in ASH Clinical News. Aaron Gerds, MD, Editor-in-Chief of ASH Clinical News and Deputy Director for Research at Cleveland Clinic Cancer Center, recently delved into this thought-provoking topic, arguing the benefits of presenting research findings instead of including conclusive statements that leave room for interpretation. Read more here.